DRKS00000781
Recruiting
Not Applicable
on-interventional study about safety and efficacy of chemo-therapy with Paclitaxel Stragen(R) / Eurotaxel(R) (new name of the prescription) as mono or combined therapy for routine treatment of ovarial or breast cancer with special consideration of age and BMI starting position. - ET-001
apharm GmbH0 sites1,500 target enrollmentApril 11, 2011
ConditionsBreast cancer, ovarial cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast cancer, ovarial cancer
- Sponsor
- apharm GmbH
- Enrollment
- 1500
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically secured ovarial or breast cancer.
- •Signed patient informed consent form.
Exclusion Criteria
- •Other malign diseases in the past 5 years.
- •Lack of compliance.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
on-interventional study on the safety and efficacy of an Abraxane(R) mono therapy for the therapy of patients with metasasized breast cancer with special consideration of the toxicity profilesC50Malignant neoplasm of breastDRKS00003203OnkoDataMed GmbH !450
Not yet recruiting
Phase 3
A randomized control trial to study the antibody response and side effects after the booster dose of COVID-19 vaccineCTRI/2022/01/039677Institute of Liver and Biliary Sciences
Completed
Not Applicable
A clinical study investigating the safety, efficacy and performance of the URECA CTO device.ArteriosclerosisChronic Total Occlusion(s)10003216NL-OMON55292reca B.V.40
Completed
Phase 3
BS054 Clinical StudyJPRN-jRCT2092220032Boston Scientific Japan K.K.20
Completed
Not Applicable
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.CD20-positive B-cell lymphomaJPRN-UMIN000003641Japanese Red Cross Medical Center15